Moderator: Natalie Grover, Reporter, Endpoints News.
Oreola Donini, PhD, Chief Scientific Officer, Soligenix, Inc.
Daria Hazuda, VP, Infectious Diseases Discovery & Chief Scientific Officer, MRL Cambridge Exploratory Center, Merck & Co
Sumati Nambiar, Director of the Division of Anti-Infectives, Center for Drug Evaluation and Research (CDER), FDA
Florence Séjourné, CEO, Da Volterra
Ongoing innovation is needed to address the growing threat of antimicrobial resistance. The current pipeline is mostly comprised of traditional, small-molecule antibiotics based on existing antibiotic classes.
More and different science will be needed to shift the treatment paradigm from traditional broad-spectrum antibiotics to more focused treatments and novel approaches. These next-generation tools may help improve outcomes for patients by better targeting resistant pathogens and/or reducing the impact on the microbiome. However, novel approaches face important scientific, regulatory and economic challenges that limit investment in their development.
This panel will highlight research and collaborations to develop new tools to tackle AMR and provide an update on efforts to facilitate development and uptake of innovation. While these tools may be years from approval, policy engagement to address identified barriers must begin now. Available starting June 8 on BIO Virtual website.